Consistent with this observation, publicly available human transcriptomic data revealed that CHRNA2 was readily detectable in healthy livers and that individuals with obesity or type 2 diabetes, which commonly appear with MASH as its risk factors and comorbidities, tended to have higher hepatic CHRNA2 expression than healthy control subjects (S1D–S1F Fig). This evidence concerns the gene CHRNA2 and type 2 diabetes mellitus.